Outcomes following 50 mg versus 100 mg alemtuzumab in reduced-intensity conditioning stem cell transplants for acute myeloid leukaemia and poor risk myelodysplasia

Eleni Tholouli; Effie Liakopoulou; Hayley M. Greenfield; Bronwen E. Shaw; Sudhir Tauro; Jennifer L. Byrne; Mike Dennis; John Burthem; Guy S. Lucas; Charles Craddock; Nigel H. Russell; John A. Liu Yin

doi:10.1111/j.1365-2141.2008.07184.x

Outcomes following 50 mg versus 100 mg alemtuzumab in reduced-intensity conditioning stem cell transplants for acute myeloid leukaemia and poor risk myelodysplasia

Eleni Tholouli, Effie Liakopoulou, Hayley M. Greenfield, Bronwen E. Shaw, Sudhir Tauro, Jennifer L. Byrne, Mike Dennis, John Burthem, Guy S. Lucas, Charles Craddock, Nigel H. Russell, John A. Liu Yin

Research output: Contribution to journal › Letter › peer-review

7 Citations (Scopus)

Original language	English
Pages (from-to)	318-320
Number of pages	3
Journal	British Journal of Haematology
Volume	142
Issue number	2
DOIs	https://doi.org/10.1111/j.1365-2141.2008.07184.x
Publication status	Published - Jul 2008

Keywords

alemtuzumab
acute myeloid leukaemia
poor risk myelodysplasia
reduced intensity conditioning
stem cell transplant
VERSUS-HOST-DISEASE
BONE-MARROW
MALIGNANCIES
REGIMEN

Access to Document

10.1111/j.1365-2141.2008.07184.x

Cite this

Tholouli, E., Liakopoulou, E., Greenfield, H. M., Shaw, B. E., Tauro, S., Byrne, J. L., Dennis, M., Burthem, J., Lucas, G. S., Craddock, C., Russell, N. H., & Yin, J. A. L. (2008). Outcomes following 50 mg versus 100 mg alemtuzumab in reduced-intensity conditioning stem cell transplants for acute myeloid leukaemia and poor risk myelodysplasia. British Journal of Haematology, 142(2), 318-320. https://doi.org/10.1111/j.1365-2141.2008.07184.x

@article{54950ee5df46416bb35ba88ba6e2622a,

title = "Outcomes following 50 mg versus 100 mg alemtuzumab in reduced-intensity conditioning stem cell transplants for acute myeloid leukaemia and poor risk myelodysplasia",

keywords = "alemtuzumab, acute myeloid leukaemia, poor risk myelodysplasia, reduced intensity conditioning, stem cell transplant, VERSUS-HOST-DISEASE, BONE-MARROW, MALIGNANCIES, REGIMEN",

author = "Eleni Tholouli and Effie Liakopoulou and Greenfield, {Hayley M.} and Shaw, {Bronwen E.} and Sudhir Tauro and Byrne, {Jennifer L.} and Mike Dennis and John Burthem and Lucas, {Guy S.} and Charles Craddock and Russell, {Nigel H.} and Yin, {John A. Liu}",

year = "2008",

month = jul,

doi = "10.1111/j.1365-2141.2008.07184.x",

language = "English",

volume = "142",

pages = "318--320",

journal = "British Journal of Haematology",

issn = "0007-1048",

publisher = "Wiley",

number = "2",

}

Tholouli, E, Liakopoulou, E, Greenfield, HM, Shaw, BE, Tauro, S, Byrne, JL, Dennis, M, Burthem, J, Lucas, GS, Craddock, C, Russell, NH & Yin, JAL 2008, 'Outcomes following 50 mg versus 100 mg alemtuzumab in reduced-intensity conditioning stem cell transplants for acute myeloid leukaemia and poor risk myelodysplasia', British Journal of Haematology, vol. 142, no. 2, pp. 318-320. https://doi.org/10.1111/j.1365-2141.2008.07184.x

Outcomes following 50 mg versus 100 mg alemtuzumab in reduced-intensity conditioning stem cell transplants for acute myeloid leukaemia and poor risk myelodysplasia. / Tholouli, Eleni; Liakopoulou, Effie; Greenfield, Hayley M. et al.
In: British Journal of Haematology, Vol. 142, No. 2, 07.2008, p. 318-320.

Research output: Contribution to journal › Letter › peer-review

TY - JOUR

T1 - Outcomes following 50 mg versus 100 mg alemtuzumab in reduced-intensity conditioning stem cell transplants for acute myeloid leukaemia and poor risk myelodysplasia

AU - Tholouli, Eleni

AU - Liakopoulou, Effie

AU - Greenfield, Hayley M.

AU - Shaw, Bronwen E.

AU - Tauro, Sudhir

AU - Byrne, Jennifer L.

AU - Dennis, Mike

AU - Burthem, John

AU - Lucas, Guy S.

AU - Craddock, Charles

AU - Russell, Nigel H.

AU - Yin, John A. Liu

PY - 2008/7

Y1 - 2008/7

KW - alemtuzumab

KW - acute myeloid leukaemia

KW - poor risk myelodysplasia

KW - reduced intensity conditioning

KW - stem cell transplant

KW - VERSUS-HOST-DISEASE

KW - BONE-MARROW

KW - MALIGNANCIES

KW - REGIMEN

U2 - 10.1111/j.1365-2141.2008.07184.x

DO - 10.1111/j.1365-2141.2008.07184.x

M3 - Letter

C2 - 18492100

SN - 0007-1048

VL - 142

SP - 318

EP - 320

JO - British Journal of Haematology

JF - British Journal of Haematology

IS - 2

ER -